Diabetes Metab J.  2014 Apr;38(2):143-149. 10.4093/dmj.2014.38.2.143.

Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance

• Esteghamati A
• Noshad S
• Mousavizadeh M
• Zandieh A
• Nakhjavani M

• KMID: 2280705
• DOI: http://doi.org/10.4093/dmj.2014.38.2.143

Abstract

BACKGROUND
Previous studies evaluating the relationship between serum vaspin concentrations and metabolic syndrome (MetS) have yielded contrasting results. Additionally, contribution of general and abdominal obesity, chronic inflammation, and insulin resistance to this relationship remains unknown.
METHODS
In a cross-sectional setting, we investigated the association between vaspin and MetS in 145 subjects ranging from normoglycemia to type 2 diabetes. Vaspin concentrations were measured using enzyme-linked immunosorbent assay.
RESULTS
Women had 29% higher vaspin concentrations compared with men. Subjects with MetS (51% of all participants) had higher vaspin concentrations (P=0.019 in women and P<0.001 in men). In logistic regression, vaspin significantly predicted raised fasting plasma glucose (P<0.001), and raised triglycerides (P<0.001) after controlling for age in both sexes. Moreover, vaspin was the significant predictor for reduced high-density lipoprotein cholesterol and raised waist circumference in women and men, respectively. Considering MetS as a whole, vaspin predicted MetS even after adjustment for age, medications, diabetes, total cholesterol, and waist circumference in both sexes (odds ratio [OR], 3.88; 95% confidence interval [CI], 1.36 to 11.05; P=0.011 for women; OR, 3.16; 95% CI, 1.28 to 7.78; P=0.012 for men). However, this relationship rendered nonsignificant after introducing homeostasis model assessment of insulin resistance (HOMA-IR) in women (P=0.089) and high-sensitivity C-reactive protein (P=0.073) or HOMA-IR in men (P=0.095).
CONCLUSION
Vaspin is associated with some but not all components of MetS. Vaspin is a predictor of MetS as a single entity, independent of obesity. This relationship is largely ascribed to the effects of insulin resistance and chronic inflammation.

Keyword

Abdominal obesity; Inflammation; Insulin resistance; Metabolic syndrome; Vaspin

MeSH Terms

Blood Glucose
C-Reactive Protein
Cholesterol
Enzyme-Linked Immunosorbent Assay
Fasting
Female
Homeostasis
Humans
Inflammation
Insulin Resistance*
Insulin*
Lipoproteins
Logistic Models
Male
Obesity
Obesity, Abdominal
Triglycerides
Waist Circumference
C-Reactive Protein
Cholesterol
Insulin
Lipoproteins
Triglycerides

Figure

• 

  Fig. 1 Vaspin concentrations stratified according to sex/glycemic status (A), or sex/number of metabolic abnormalities (B). Given the nonnormal distribution of vaspin, values are presented as median (25% to 75% percentiles) (boxes), along with 5% to 95% percentiles (whiskers). NGT, normal glucose tolerance; IFG, impaired fasting glucose; DM, diabetes mellitus.

Reference

1. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet. 2005; 366:1059–1062.

2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365:1415–1428.

3. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003; 24:278–301.

4. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008; 29:2959–2971.

5. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005; 102:10610–10615.

6. Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, Broch M, Aguilar C, Olona M, Porras JA, Hernandez M, Sabench F, del Castillo D, Richart C. New adipokines vaspin and omentin: circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011; 12:60.

7. Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf). 2011; 75:628–635.

8. Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract. 2009; 84:325–328.

9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419.

10. American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013; 36:Suppl 1. S11–S66.

11. Esteghamati A, Ashraf H, Rashidi A, Meysamie A. Waist circumference cut-off points for the diagnosis of metabolic syndrome in Iranian adults. Diabetes Res Clin Pract. 2008; 82:104–107.

12. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Bluher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008; 57:372–377.

13. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism. 2011; 60:63–70.

14. Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 2011; 60:544–549.

15. Chang HM, Park HS, Park CY, Song YS, Jang YJ. Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects. Metabolism. 2010; 59:1276–1281.

16. Chang HM, Lee HJ, Park HS, Kang JH, Kim KS, Song YS, Jang YJ. Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity (Silver Spring). 2010; 18:2105–2110.

17. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11:85–97.

18. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34:2–11.

19. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T, Takahashi T. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res. 2008; 36:625–629.

20. Korner A, Neef M, Friebe D, Erbs S, Kratzsch J, Dittrich K, Bluher S, Kapellen TM, Kovacs P, Stumvoll M, Bluher M, Kiess W. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int J Obes (Lond). 2011; 35:578–586.